Company Buyout Price: CRISPR Therapeutics AG (CRSP)

Graphic logo of CRISPR (CRSP)

CRISPR Therapeutics AG (CRSP) stands at the forefront of the bio-revolution, correcting genetic defects using "molecular scissors" to eradicate hereditary pathologies. This daily price action reflects an Enterprise Value market trend of 3390.95. Business growth is driven by the launch of Casgevy therapy, advancements in CAR-T, and a substantial liquidity reserve. The stability of R&D processes is guaranteed by a staff of top biochemists and international law experts.

CRSP: CRISPR Enterprise Value 11/23/2025 - 10/31/2026

CRISPR Therapeutics AG (CRSP) - metric breakdowns and financial figures

- stock quotes and analyst forecast:
Price Performance Chart CRISPR Therapeutics Inc|CRSP - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization CRISPR Therapeutics|CRSP - Total Company Value
- balance sheet equity data:
Share Book Value CRISPR Therapeutics|CRSP - Book Capitalization|Capitalization to Book Value Ratio crisprtx.com|CRSP - Aggregate Company Assets
- debt level and financial liquidity data:
Debt to Equity Ratio CRISPR Therapeutics AG|CRSP - Long-Term Debt to Capital|Short-Term Debt to Capital crisprtx.com|CRSP - Company Aggregate Debts|Debt to Book Value CRISPR Therapeutics|CRSP - Company Long-Term Debt|Company Short-Term Loans and Borrowings CRISPR Therapeutics|Interim Coverage Ratio crisprtx.com
- earnings and valuation multiples information:
CRSP - Company Net Income
Summary company analytics:CRSP - CRISPR Therapeutics Inc
Flagship merchandise of CRISPR Therapeutics AG

Enterprise value combines market capitalization with net debt, reflecting the actual price of a full business acquisition inclusive of liquid assets. For gene-editing pioneer CRISPR Therapeutics AG (CRSP), this metric demonstrates how its status as an innovation leader and the success of its first commercial therapies influence the overall valuation, which is clearly supported by the historical enterprise value trend.

Competitors of CRISPR Therapeutics AG (CRSP)

Value Adjusted for Debt and Cash TEM|QGEN - Total Company Value|Company Buyout Price Isis Pharmaceuticals IONS|Repligen Corporation (RGEN) - Total Company Value|Full Business Value RNA (aviditybiosciences.com)|WGS (GeneDx) - Enterprise Value|Business Value RARE (Ultragenyx Pharmaceutical Inc.)|Total Company Value Beam Therapeutics Corp (BEAM)|Sarepta Corp - Business Value|Enterprise Value TWST (Twist Bioscience)|Enterprise Value 10xgenomics.com TXG|Intellia Therapeutics, Inc. - Enterprise Value|Stoke Therapeutics Inc (STOK) - Real Price to Acquire Entire Company|BioLife Corp (BLFS) - Total Company Value|Wave Pharma - Value Adjusted for Debt and Cash|MAZE (Maze Therapeutics Inc) - Enterprise Value|sionnatx.com (SION) - Company Buyout Price|Total Company Value Prime Medicine (PRME)|Company Buyout Price Taysha Gene Therapies Inc|Total Company Value uniQure Corp QURE|MGTX (MeiraGTx Corp) - Full Business Value|RGNX - Total Company Value|Value Adjusted for Debt and Cash SLDB (solidbio.com)|OCGN (Ocugen) - Real Price to Acquire Entire Company|Pacific Biosciences of California, Inc. - Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company BNTC|DSGN (Design Corp) - Aggregate Business Value|Enterprise Value RCKT|FDMT (4dmoleculartherapeutics.com) - Value Adjusted for Debt and Cash|Enterprise Value LXEO (Lexeo Therapeutics, Inc.)|Korro Bio Inc. (KRRO) - Total Enterprise Value|EDIT - Total Company Value|Value Adjusted for Debt and Cash SLN (Silence Therapeutics Corp)|PRQR: Enterprise Value|Codexis (CDXS) - Enterprise Value|Total Company Value Sangamo Therapeutics, Inc.|Nautilus Biotechnology Inc - Full Business Value|Enterprise Value MGX|DTIL - Total Enterprise Value|Generation Bio - Real Price to Acquire Entire Company|Enterprise Value boundlessbio.com BOLD|XCUR: Real Price to Acquire Entire Company|Imunon, Inc. - Aggregate Business Value|PHIO: Enterprise Value|MBIO - Company Buyout Price|RNAZ (TransCode Therapeutics Inc.) - Enterprise Value|Real Price to Acquire Entire Company Bionano (BNGO)|Total Company Value Applied DNA Sciences, Inc. (APDN)|Company Buyout Price bluebird bio Inc.|ImmunoPrecise Antibodies Ltd. - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash OMGA|Singular Genomics Systems - Enterprise Value|RGLS - Enterprise Value|SYRS: Enterprise Value|Full Takeover Company Value Telesis Bio Inc. TBIO|TCON (TRACON) - Enterprise Value|Real Price to Acquire Entire Company Unity Biotechnology, Inc (UBX)